TY - JOUR
T1 - Urine trefoil factors as prognostic biomarkers in chronic kidney disease
AU - Yamanari, Toshio
AU - Sugiyama, Hitoshi
AU - Tanaka, Keiko
AU - Morinaga, Hiroshi
AU - Kitagawa, Masashi
AU - Onishi, Akifumi
AU - Ogawa-Akiyama, Ayu
AU - Kano, Yuzuki
AU - Mise, Koki
AU - Ohmoto, Yasukazu
AU - Shikata, Kenichi
AU - Wada, Jun
N1 - Funding Information:
Jun Wada received speaker honoraria from Astellas, Boehringer Ingelheim, Daiichi Novartis, Sankyo, and Tanabe Mitsubishi and received grant support from Astellas, Bayer, Baxter, Chugai, Daiichi Sankyo, Kissei, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Otsuka, Pf izer, Teijin, Torii, and Takeda. Kenichi Shikata received speaker honoraria from Ono, Novartis, MSD, Astellas, Tanabe Mitsubishi, Boehringer Ingelheim, Novo Nordisk, and Astra Zeneka and received grant support from Takeda, Tanabe Mitsubishi, Kyowa Hakko Kirin, and Japan Eli Lilly. The other authors declare that they have no conflicts of interest.
Funding Information:
The authors express their sincere appreciation to all of the participating patients and to the collaborating physicians and other medical staff in their department for their important contributions to the study. They also thank Brian Quinn for the editorial support for preparation of the manuscript. A portion of this study was supported by JSPS KAKENHI Grant no JP16K09616 to Hitoshi Sugiyama.
Publisher Copyright:
© 2018 Toshio Yamanari et al.
PY - 2018
Y1 - 2018
N2 - Introduction. Trefoil factor family (TFF) peptides are increased in serum and urine in patients with chronic kidney disease (CKD). However, whether the levels of TFF predict the progression of CKD remains to be elucidated. Methods. We determined the TFF levels using peptide-specific ELISA in spot urine samples and performed a prospective cohort study. The association between the levels of urine TFFs and other urine biomarkers as well as the renal prognosis was analyzed in 216 CKD patients (mean age: 53.7 years, 47.7% female, 56.9% with chronic glomerulonephritis, and mean EGFR: 58.5 ml/min/1.73 m2). Results. The urine TFF1 and TFF3 levels significantly increased with the progression of CKD stages, but not the urine TFF2 levels. The TFF1 and TFF3 peptide levels predicted the progression of CKD ≥ stage 3b by ROC analysis (AUC 0.750 and 0.879, resp.); however, TFF3 alone predicted CKD progression in a multivariate logistic regression analysis (odds ratio 3.854, 95% confidence interval 1.316-11.55). The Kaplan-Meier survival curves demonstrated that patients with a higher TFF1 and TFF3 alone, or in combination with macroalbuminuria, had a significantly worse renal prognosis. Conclusion. The data suggested that urine TFF peptides are associated with renal progression and the outcomes in patients with CKD.
AB - Introduction. Trefoil factor family (TFF) peptides are increased in serum and urine in patients with chronic kidney disease (CKD). However, whether the levels of TFF predict the progression of CKD remains to be elucidated. Methods. We determined the TFF levels using peptide-specific ELISA in spot urine samples and performed a prospective cohort study. The association between the levels of urine TFFs and other urine biomarkers as well as the renal prognosis was analyzed in 216 CKD patients (mean age: 53.7 years, 47.7% female, 56.9% with chronic glomerulonephritis, and mean EGFR: 58.5 ml/min/1.73 m2). Results. The urine TFF1 and TFF3 levels significantly increased with the progression of CKD stages, but not the urine TFF2 levels. The TFF1 and TFF3 peptide levels predicted the progression of CKD ≥ stage 3b by ROC analysis (AUC 0.750 and 0.879, resp.); however, TFF3 alone predicted CKD progression in a multivariate logistic regression analysis (odds ratio 3.854, 95% confidence interval 1.316-11.55). The Kaplan-Meier survival curves demonstrated that patients with a higher TFF1 and TFF3 alone, or in combination with macroalbuminuria, had a significantly worse renal prognosis. Conclusion. The data suggested that urine TFF peptides are associated with renal progression and the outcomes in patients with CKD.
UR - http://www.scopus.com/inward/record.url?scp=85045728578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045728578&partnerID=8YFLogxK
U2 - 10.1155/2018/3024698
DO - 10.1155/2018/3024698
M3 - Article
C2 - 29850501
AN - SCOPUS:85045728578
VL - 2018
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 3024698
ER -